Cefmenoxime sodium | CAS# 65085-02-1 (Na+) | cephalosporin antibiotic

MedKoo Cat#: 412517 | Name: Cefmenoxime sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefmenoxime sodium is the ssalt form of Cefmenoxime (free base), a cephalosporin antibiotic administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms. It is a potent inhibitor of Enterobacteriaceae, and is resistant to beta-lactamase-initiated hydrolysis. The drug has a high success rate against many types of infection.

Chemical Structure

Cefmenoxime sodium

CAS#65085-02-1 (sodium)

Theoretical Analysis

MedKoo Cat#: 412517

Name: Cefmenoxime sodium

CAS#: 65085-02-1 (sodium)

Chemical Formula: C16H16N9NaO5S3

Exact Mass: 533.0334

Molecular Weight: 533.53

Elemental Analysis: C, 36.02; H, 3.02; N, 23.63; Na, 4.31; O, 14.99; S, 18.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

75738-58-8 (HCl) 65085-01-0 (free base) 65085-02-1 (sodium)

Synonym

Cefmenoxime sodium; UNII-RB30TNF2RT

IUPAC/Chemical Name

sodium (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

RXYOYKDBLLALFG-FAIYLGIWSA-M

InChi Code

InChI=1S/C16H17N9O5S3.Na/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7;/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29);/q;+1/p-1/b21-8-;/t9-,13-;/m1./s1

SMILES Code

CO/N=C(c1nc(N)sc1)\C(N[C@H]2[C@H]3SCC(CSc4n(C)nnn4)=C(C([O-])=O)N3C2=O)=O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 533.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shimizu K. [Cefmenoxime]. Jpn J Antibiot. 1983 Jun;36(6):1165-72. Japanese. PMID: 6317903. 2: Campoli-Richards DM, Todd PA. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Aug;34(2):188-221. doi: 10.2165/00003495-198734020-00002. PMID: 3304966. 3: Stamm JM, Girolami RL, Shipkowitz NL, Bower RR. Antimicrobial activity of cefmenoxime (SCE-1365). Antimicrob Agents Chemother. 1981 Mar;19(3):454-60. doi: 10.1128/aac.19.3.454. PMID: 6264846; PMCID: PMC181453. 4: Reitberg DP, Cumbo TJ, Smith IL, Schentag JJ. Effect of protein binding on cefmenoxime steady-state kinetics in critical patients. Clin Pharmacol Ther. 1984 Jan;35(1):64-73. doi: 10.1038/clpt.1984.10. PMID: 6317272. 5: Onks DL, Harris JF, Robertson AF. Cefmenoxime and bilirubin: competition for albumin binding. Pharmacol Toxicol. 1991 May;68(5):329-31. doi: 10.1111/j.1600-0773.1991.tb01248.x. PMID: 1946178. 6: Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. doi: 10.1128/aac.19.1.56. PMID: 6941742; PMCID: PMC181357. 7: Tan JS, File TM Jr. Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections. Am J Med. 1984 Dec 21;77(6A):51-2. doi: 10.1016/s0002-9343(84)80075-3. PMID: 6097125. 8: Baker RL, Perkins RL. Cefmenoxime: clinical evaluation. Am J Med. 1984 Dec 21;77(6A):53-9. doi: 10.1016/s0002-9343(84)80076-5. PMID: 6097126. 9: Sennello LT, Quinn D, Rollins DE, Tolman KG, Sonders RC. Effect of probenecid on the pharmacokinetics of cefmenoxime. Antimicrob Agents Chemother. 1983 Jun;23(6):803-7. doi: 10.1128/aac.23.6.803. PMID: 6311084; PMCID: PMC184968. 10: Duncker GI, Reich U, Krausse R. Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6. doi: 10.1159/000310505. PMID: 7816419.